Chickenpox
MONDO:0005700A contagious childhood disorder caused by the varicella zoster virus. It is transmitted via respiratory secretions and contact with chickenpox blister contents. It presents with a vesicular skin rash, usually associated with fever, headache, and myalgias. The pruritic fluid-filled vesicles occur 10-21 days after exposure and last for 3-4 days. An additional 3-4 days of malaise follows before the affected individual feels better. An individual is contagious 1-2 days prior to the appearance of the blisters until all blisters are crusted over. Generally, healthy individuals recover without complications.
Also known as: Varicella, chicken pox, chicken pox infection, chickenpox, varicella
29 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
Could a new vaccine beat chickenpox? large trial underway
⭐️ VACCINE ⭐️ Not yet recruitingThis study tests a new chickenpox vaccine called NBP608 in about 780 children aged 1 to 12 years. The vaccine is compared to licensed vaccines to see how well it triggers immunity and if it is safe. Children receive one or two shots, and researchers monitor their immune response …
Phase: PHASE3 • Sponsor: SK Bioscience Co., Ltd. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 14:00 UTC
-
New chickenpox vaccine trial aims to protect 300 kids
⭐️ VACCINE ⭐️ Not yet recruitingThis study tests a new chickenpox vaccine in 300 healthy children aged 1 to 12 years. All children will receive one dose of the vaccine. Researchers will check if the vaccine triggers a strong immune response and is safe to use.
Phase: PHASE3 • Sponsor: Sinovac (Dalian) Vaccine Technology Co., Ltd. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 13:07 UTC
-
MRNA vaccine aims to prevent shingles in older adults
⭐️ VACCINE ⭐️ Not yet recruitingThis phase 2 trial tests a new mRNA vaccine called IN001 for preventing shingles in healthy adults aged 50 to 79. Researchers will compare three dose levels of IN001 against the existing Shingrix vaccine to see how safe and effective they are. The study involves 480 participants …
Phase: PHASE2 • Sponsor: Shenzhen Shenxin Biotechnology Co., Ltd • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 07:54 UTC
-
Can a new Four-in-One vaccine match the gold standard for childhood protection?
Prevention Not yet recruitingThis study tests an investigational vaccine that combines protection against measles, mumps, rubella, and chickenpox (varicella) in a single shot. It will be given as a second dose to healthy children aged 4 to 6 years who have already received a first dose of a similar vaccine. …
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Prevention
Last updated Aug 05, 2026 00:00 UTC
-
New shingles shot shows promise in Mid-Stage trial
Prevention Not yet recruitingThis study tests a new shingles vaccine in 135 healthy adults aged 50 and older. Researchers will compare the immune response and safety of the new vaccine against an existing one to find the best dose. The goal is to prevent shingles, a painful rash caused by the chickenpox viru…
Phase: PHASE2 • Sponsor: CHA Vaccine Institute Co., Ltd. • Aim: Prevention
Last updated Jun 27, 2026 11:03 UTC
-
Could a booster shot shield transplant patients from shingles?
Prevention Not yet recruitingThis study tests whether an extra dose of the shingles vaccine (Shingrix) can boost immunity in people who have had a solid-organ transplant, like a kidney or liver. About 30% of transplant patients still get shingles after the standard two-dose vaccine, likely due to immune-supp…
Phase: PHASE2 • Sponsor: Oriol Manuel • Aim: Prevention
Last updated Jun 27, 2026 09:09 UTC